Oncolytics Biotech Inc. filed a Form 8-K on November 9, 2026, announcing translational data from patients with relapsed/refractory multiple myeloma that will be presented at the 68th American Society of Hematological Annual Meeting and Exposition.

Key Highlights

  • Data focus: Translational data from patients with relapsed/refractory multiple myeloma was disclosed, according to the filing.
  • Key finding: The data shows pelareorep's "ability to engage the immune system and to combine with standard-of-care therapies," as stated in the press release announcement.
  • Venue: The data is set to be presented at the 68th American Society of Hematological Annual Meeting and Exposition.
  • Filing date: The report and the press release (Exhibit 99.1) are both dated November 9, 2026.
  • Furnished, not filed: The company disclosed that the information "shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934."

Pelareorep Myeloma Translational Data to Be Presented at ASH 68th Annual Meeting

Oncolytics Biotech Inc. (NASDAQ:ONCY) reported via Form 8-K under Item 8.01 (Other Events) that it issued a press release on November 9, 2026, covering translational data from patients with relapsed/refractory multiple myeloma. According to the filing, the data addresses pelareorep's capacity to engage the immune system and to combine with standard-of-care therapies in this patient population.

The filing states that the data will be presented at the 68th American Society of Hematological Annual Meeting and Exposition. The company did not disclose specific patient counts, response rates, or other quantitative clinical outcomes in the 8-K text itself; those details are contained in Exhibit 99.1, the full press release attached to the filing.

The company specified that the information furnished under Item 8.01 and in Exhibit 99.1 is furnished and "shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section." The filing was signed by Kirk Look, Chief Financial Officer of Oncolytics Biotech Inc.

What Was Disclosed

Oncolytics Biotech filed an 8-K on November 9, 2026, disclosing a press release about translational data for pelareorep in relapsed/refractory multiple myeloma, to be presented at the 68th ASH Annual Meeting and Exposition.